| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
,1
* EuroMISE Center-Cardio and Institute of Hygienic Medicine and Epidemiology, and
4th Department of Internal Medicine and Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty, Charles University, Prague, Czech Republic
Abstract
Bilirubin, a major intravascular product of heme catabolism, is a potent antioxidant compound. Numerous studies have been published showing the relationship between serum bilirubin levels and atherosclerosis. In the present investigation all the epidemiological studies available on the effect of serum bilirubin levels and atherosclerotic disease were analyzed. Studies on the epidemiology of atherosclerotic diseases in relation to serum bilirubin levels were searched in the MEDLINE database. Selected studies were subdivided according to serum bilirubin levels and severity of atherosclerotic disease. Because of the limited number of females involved in the studies, only males were included into meta-analysis. Associations for ordered categorical variables (bilirubin and natural history of graded atherosclerosis) were assessed to find correlation and linear trend between analyzed variables. A stratified analysis was conducted to compare risks of clinical outcomes. Eleven relevant studies were used for analysis. A close negative relationship was found between serum bilirubin levels and severity of atherosclerosis (Spearman rank coefficient r = -0.31,P < 0.0001). The linear trend was confirmed in analysis of proportions with x2 values for both disease conditions to be very significant (P < 0.0001). Unambiguous inverse relationship between serum bilirubin levels and atherosclerosis was demonstrated in this preliminary meta-analytic study. These results indicate the importance of hem oxygenase-related products in the prevention of oxidative stress-mediated diseases.
Key Words: atherosclerosis • oxidative stress • ischemia • artery disease
This article has been cited by other articles:
|
|
 |
|
  A. D. Johnson, M. Kavousi, A. V. Smith, M.-H. Chen, A. Dehghan, T. Aspelund, J.-P. Lin, C. M. van Duijn, T. B. Harris, L. A. Cupples, et al. Genome-wide association meta-analysis for total serum bilirubin levels Hum. Mol. Genet., July 15, 2009; 18(14): 2700 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak, M. Saleh, D. S. Higginson, B. D. Paul, K. R. Juluri, and S. H. Snyder Bilirubin and glutathione have complementary antioxidant and cytoprotective roles PNAS, March 31, 2009; 106(13): 5171 - 5176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Sena, R Pedrosa, V Ferret-Sena, M. Cascais, R Roque, C Araujo, and R Couderc Interferon {beta} therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 857 - 859. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study Clin. Chem., May 1, 2008; 54(5): 851 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Perlstein, R. L. Pande, J. A. Beckman, and M. A. Creager Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak and S. H. Snyder Messenger Molecules and Cell Death: Therapeutic Implications JAMA, January 4, 2006; 295(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gullu, D. Erdogan, D. Tok, S. Topcu, M. Caliskan, T. Ulus, and H. Muderrisoglu High Serum Bilirubin Concentrations Preserve Coronary Flow Reserve and Coronary Microvascular Functions Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2289 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ollinger, M. Bilban, A. Erat, A. Froio, J. McDaid, S. Tyagi, E. Csizmadia, A. V. Graca-Souza, A. Liloia, M. P. Soares, et al. Bilirubin: A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation Circulation, August 16, 2005; 112(7): 1030 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bach Heme oxygenase-1: a therapeutic amplification funnel FASEB J, August 1, 2005; 19(10): 1216 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pflueger, A. J. Croatt, T. E. Peterson, L. A. Smith, L. V. d'Uscio, Z. S. Katusic, and K. A. Nath The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II Am J Physiol Renal Physiol, March 1, 2005; 288(3): F552 - F558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kapitulnik Bilirubin: An Endogenous Product of Heme Degradation with Both Cytotoxic and Cytoprotective Properties Mol. Pharmacol., October 1, 2004; 66(4): 773 - 779. [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Sedlak and S. H. Snyder Bilirubin Benefits: Cellular Protection by a Biliverdin Reductase Antioxidant Cycle Pediatrics, June 1, 2004; 113(6): 1776 - 1782. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Schwertner Bilirubin Concentration, UGT1A1*28 Polymorphism, and Coronary Artery Disease Clin. Chem., July 1, 2003; 49(7): 1039 - 1040. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
